Phase 1 Trial Approved to Test PRGN-3005 UltraCAR-T for Advanced Platinum-resistant Ovarian Cancer
News
Precigen is preparing to launch a Phase 1 trial to test its investigational therapy PRGN-3005 UltraCAR-T for advanced, platinum-resistant ovarian cancer, after the U.S. Food and Drug Administration (FDA) cleared its investigational ... Read more